The potential impact of CD4+ T cell activation and enhanced Th1/Th2 cytokine ratio on HIV-1 secretion in the lungs of individuals with advanced AIDS and active pulmonary infection

Pierre-Alain Rubbo; Edouard Tuaillon; Karine Bolloré; Vincent Foulongne; Arnaud Bourdin; Nicolas Nagot; Philippe Van de Perre; Claude Desgranges; Dominique Israël-Biet; Jean-Pierre Vendrell

doi:10.1016/j.clim.2011.01.007

The potential impact of CD4+ T cell activation and enhanced Th1/Th2 cytokine ratio on HIV-1 secretion in the lungs of individuals with advanced AIDS and active pulmonary infection

Clin Immunol. 2011 May;139(2):142-54. doi: 10.1016/j.clim.2011.01.007. Epub 2011 Jan 27.

Authors

Pierre-Alain Rubbo¹, Edouard Tuaillon, Karine Bolloré, Vincent Foulongne, Arnaud Bourdin, Nicolas Nagot, Philippe Van de Perre, Claude Desgranges, Dominique Israël-Biet, Jean-Pierre Vendrell

Affiliation

¹ INSERM U1058, CHRU, Montpellier 1 University, Montpellier, France. [email protected]

PMID: 21345739
DOI: 10.1016/j.clim.2011.01.007

Abstract

Bronchoalveolar lavage fluid (BALF) provides a source of mucosal CD4(+) T cells. We investigated the physiological properties of T lymphocytes from BALF and blood and their role on the dynamic of HIV-1 replication among AIDS patients with active lung infections. Pulmonary CD4(+) T cells consist mainly of effector memory cells (CD45RO(+) and CCR7(-)) with increased expression of activation markers (HLA-DR(+) and CD69(+)) when compared to the blood counterpart. We observed a high frequency of BALF cells capable of secreting HIV-1-Ags suggesting that the local lung environment may support favorable conditions for CD4(+) T lymphocytes harboring HIV-1 DNA to initiate the viral cycle. Nevertheless, the high number of IFN-γ-producing cells and the predominance of Th1 immune response in the lung could limit the secretion of HIV-1 RNA. In conclusion, the capacity of activated CD4(+) T cells to produce HIV-1 is driven by both the level and quality of cellular activation in the lung.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Acquired Immunodeficiency Syndrome / complications
Acquired Immunodeficiency Syndrome / immunology
Acquired Immunodeficiency Syndrome / virology*
Antigens, CD / metabolism
Bronchoalveolar Lavage Fluid / chemistry
Bronchoalveolar Lavage Fluid / cytology
Bronchoalveolar Lavage Fluid / immunology
Bronchoalveolar Lavage Fluid / virology
CD4-Positive T-Lymphocytes / drug effects
CD4-Positive T-Lymphocytes / immunology*
CD4-Positive T-Lymphocytes / metabolism
CD4-Positive T-Lymphocytes / pathology
CD4-Positive T-Lymphocytes / virology
CD8-Positive T-Lymphocytes / immunology
CD8-Positive T-Lymphocytes / metabolism
CD8-Positive T-Lymphocytes / pathology
Cycloheximide / pharmacology
Cytokines / metabolism*
DNA, Viral / metabolism
HIV Antigens / metabolism
HIV-1 / isolation & purification
HIV-1 / physiology*
Humans
Immunophenotyping
Interferon-gamma / metabolism
Leukocytes, Mononuclear / drug effects
Leukocytes, Mononuclear / immunology
Leukocytes, Mononuclear / metabolism
Leukocytes, Mononuclear / virology
Lung / immunology
Lung / metabolism
Lung / virology*
Lymphocyte Activation / immunology*
RNA, Viral / metabolism
Receptors, CCR5
Receptors, CXCR4
Respiratory Tract Infections / etiology
Respiratory Tract Infections / immunology*
T-Lymphocyte Subsets / immunology
T-Lymphocyte Subsets / metabolism
T-Lymphocyte Subsets / pathology
T-Lymphocyte Subsets / virology
Viral Load / immunology
Viral Tropism / genetics
Virus Replication / drug effects
Virus Replication / immunology*

Substances

Antigens, CD
CXCR4 protein, human
Cytokines
DNA, Viral
HIV Antigens
RNA, Viral
Receptors, CCR5
Receptors, CXCR4
Interferon-gamma
Cycloheximide